This site is intended for healthcare professionals
Latest drug news
  • Home
  • /
  • News
  • /
  • 2013
  • /
  • 01
  • /
  • Nexavar (Bayer) success in Phase III trial for Thy...
Drug news

Nexavar (Bayer) success in Phase III trial for Thyroid Cancer

Read time: 1 mins
Last updated:5th Jan 2013
Published:5th Jan 2013
Source: Pharmawand
Bayer HealthCare Pharmaceuticals and Onyx Pharmaceuticals have announced that a Phase III trial of Nexavar (sorafenib) tablets in patients with locally advanced or metastatic radioactive iodine (RAI)-refractory differentiated Thyroid Cancer has met its primary endpoint of a statistically significant improvement in progression-free survival. The study, called DECISION, evaluated the efficacy and safety of Nexavar compared to placebo. The safety and tolerability were generally consistent with the known profile of Nexavar. Detailed efficacy and safety analysis from this study are expected to be presented at an upcoming medical meeting.

Learning Zones

The Learning Zones are an educational resource for healthcare professionals that provide medical information on the epidemiology, pathophysiology and burden of disease, as well as diagnostic techniques and treatment regimens.